Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05520788 | Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing(CCGLC-006) | recruiting | — | 200 | Tongji HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05557578 | GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence(GOT) | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 |
| Feb 11, 2025 |
| clinicaltrials |
| NCT05880472 | Percutaneous Holmium Injection in Pancreatic Cancer(SLOTH-2a) | active not recruiting | N/A | 6 | Radboud University Medical CenterOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05920863 | Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors | recruiting | Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05984511 | TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT | recruiting | N/A | 234 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | enrolling by invitation | Phase 1 / Phase 2 | 20 | Siriraj HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05532059 | Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma | recruiting | Phase 2 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05596630 | Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC | recruiting | N/A | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06542796 | Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma | recruiting | N/A | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06750861 | QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC | not yet recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06782412 | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types(FAPIDO) | recruiting | Phase 2 / Phase 3 | 109 | KU LeuvenOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06813508 | Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH(BOMASH) | recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06815172 | PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos) Study of Risk Factors for Exocrine Pancreatic Neoplasms.(PARA) | active not recruiting | — | 500 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06333561 | HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | recruiting | — | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06718257 | Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma | recruiting | — | 300 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06806579 | Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma(ARTE) | recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06807112 | The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma | not yet recruiting | — | 39 | Charles University, Czech RepublicOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06387342 | Namodenoson Treatment of Advanced Pancreatic Cancer | recruiting | Phase 2 | 20 | Can-Fite BioPharmaINDUSTRY | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06651346 | Cell-Surface Plectin in the Diagnosis of Cholangiocarcinoma from ERCP-directed Biliary Samples | not yet recruiting | — | 100 | University of VirginiaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06789679 | Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer | recruiting | Phase 2 | 128 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05841420 | Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer | recruiting | Phase 2 | 98 | Morten LadekarlOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06492395 | Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT | recruiting | Phase 3 | 178 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06798194 | Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma | not yet recruiting | — | 300 | Chinese PLA General HospitalOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03695952 | A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors | active not recruiting | — | 100 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04308174 | Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer(DEBATE) | active not recruiting | Phase 2 | 45 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04986930 | mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma(SABER) | active not recruiting | Phase 2 | 92 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06707233 | Y-90 SIRT for Unresectable HCC Larger Than 7cm | recruiting | Phase 2 | 33 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06792097 | Ga-68 Dolacga PET Scan in HCC Under RFA(HCC; RFA) | not yet recruiting | — | 10 | National Taiwan University HospitalOTHER | 0 | Jan 24, 2025 | clinicaltrials |
| NCT06774170 | Structured Follow-up Intervention on Glucose Status After Pancreatic Cancer Surgery(FiGluR) | enrolling by invitation | N/A | 40 | Dokuz Eylul UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06788353 | Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma | recruiting | — | 500 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT05932836 | An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC | active not recruiting | — | 165 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06334965 | Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort(OPERANDI-HCC) | recruiting | N/A | 180 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06607276 | Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE(ACHIEVE) | recruiting | Phase 2 | 122 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06777017 | Can Hepatic-splenic Elastography Predict the Risk of Hepatocellular Recurrence After Radiofrequency Ablation?(ELASTORFA) | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06774768 | Use of Machine-learning Algorithms, Biomarkers and Measures of Quality of Life to Personalize Medical Management of Liver and Heart Transplant Recipients(DARE) | not yet recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06622031 | TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT | recruiting | N/A | 42 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06572813 | Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer(CISPD-7) | recruiting | Phase 1 / Phase 2 | 63 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06664021 | Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 60 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06767579 | Comparison of the Incidence of Delirium Caused by Different Anesthetic Agents in Patients Undergoing Liver Transplantation | recruiting | — | 350 | Yonsei UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04615143 | Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC(TALENT) | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06766643 | Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer | recruiting | Phase 2 | 130 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06762782 | Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery | recruiting | Phase 2 | 276 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06764134 | Assessing Pancreatic Fistula Rates After Distal Pancreatectomy Using AEON Endostapler(AEON-DP) | recruiting | — | 110 | University Hospital HeidelbergOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | active not recruiting | Phase 1 / Phase 2 | 64 | Emory UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04803994 | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | recruiting | Phase 3 | 434 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 6 | Jan 7, 2025 | clinicaltrials |
| NCT06759090 | Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 43 | Zhejiang UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT04295317 | PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery | active not recruiting | Phase 2 | 65 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT01954992 | Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | recruiting | Phase 3 | 480 | Eleison Pharmaceuticals LLC.INDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05218889 | Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Dec 31, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 11, 2025source: clinicaltrials